Oxford BioTherapeutics Revenue and Competitors

Oxford BioTherapeutics is a clinical stage oncology company; based in Oxford, UK, Morristown and San Jose, USA; with a pipeline of first-in-class immuno-oncology (IO) and antibody-drug conjugate (ADC) based therapies designed to fulfil major unmet patient needs in the field of cancer. OBT's IO discovery process provides unique insights into the cancer - immune cell synapse and has identified several novel IO candidates, bispecific antibodies and CAR-T targets for cancer therapy. OBT's platforms are designed to discover novel therapeutic targets and engineer antibodies to those targets, including CAR-T, other T-cell and NK cell-mediated cytotoxicity (ADCC) therapeutics to best address difficult-to-treat cancers. A major differentiator between OBTs discovery platform and other approaches is the retention of the link between individual patient samples through to the design of therapeutic antibodies and diagnostic patient selection tools, increasing the overall successful transition into clinical development. OBT's clinical lead program is OBT076, currently in a U.S. Phase I Clinical Trial in Patients with Advanced Solid Tumors. OBT076 is in development for a number of tumors including HER2 negative breast cancer, triple-negative metastatic breast cancer, gastric, bladder, ovarian and lung cancer, where CD205 is overexpressed. A second clinical bispecific program is partnered with Boehringer Ingelheim. OBT's pipeline and development capabilities have been validated through multiple strategic partnerships including with world leaders in therapeutic antibody development (such as Boehringer Ingelheim, Amgen, Alere, BioWa, Medarex (BMS), Immunogen, Nerviano, WuXi and Menarini). OBT has a strong oncology focused management team and board with significant experience in developing IO and antibody-based therapies. Company Leadership Christian Rohlff, CEO Rahim Fandi, CMO